Evidence map›Paper›PMID 42793789›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study.

Nur Ecer, Mehmet Harman

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nur EcerDepartment of Dermatology and Venereology, Gazi Yaşargil Training and Research Hospital, 21070 Diyarbakır, Türkiye.ORCID 0000-0002-5837-377X
Mehmet HarmanDepartment of Dermatology and Venereology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab induces prolonged B-cell depletion and may alter protective antibody levels, but longitudinal antibody to hepatitis B surface antigen (anti-HBs) patterns in pemphigus vulgaris remain poorly characterized. This study evaluated anti-HBs levels and seroprotection after rituximab and explored associated factors.

Indexed as

anti-HBshepatitis B viruspemphigus vulgarisrituximabseroprotection

Identifiers

PMID42793789
PMCPMC13605555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.